Theravance Biopharma, Inc.【TBPH】 業績推移・財務諸表

機能の使い方
(単位:千ドル) 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25
売上高 945 2,974 6,336 1,433 20,401 7,134 10,698 3,893 18,410 5,471 19,075 5,692 3,087 3,509 4,275 4,515 8,319 23,476 12,838 15,737 5,338 26,150 12,427 29,499 19,862 15,008 18,257 18,730 14,257 12,914 13,194 14,946 13,196 11,050 12,451 14,649 10,417 13,749 15,693 17,565 14,503 14,256 16,868 18,754 15,388 26,195 19,990 45,891
売上成長率(%) - - - - 6.8 6.1 83.8 18.5 144.7
売上原価 188 279 369 3,222 371 505 581 3,201 778 638 332 1,146 565 1,364 985 3,116 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
研究開発費 41,723 46,283 38,324 42,192 36,019 30,377 30,367 32,402 35,678 32,069 31,951 42,014 40,565 42,927 39,343 51,052 47,765 48,621 52,693 52,269 53,818 46,399 52,006 67,025 66,013 62,404 67,371 65,165 67,599 51,093 43,739 31,226 23,253 15,571 9,867 14,701 14,572 9,425 8,311 8,313 8,968 9,954 9,268 9,453 11,452 10,490 8,112 7,360
販売管理費 19,052 13,118 17,705 21,772 21,748 21,545 22,845 24,064 23,596 20,261 20,286 20,366 20,786 24,339 20,944 29,523 24,704 25,007 21,890 25,457 25,186 22,227 25,622 33,046 26,325 24,780 27,501 30,055 30,550 25,931 21,299 21,516 19,121 16,986 16,277 15,968 19,183 19,278 16,142 15,492 16,742 17,056 16,875 18,501 18,370 18,430 18,333 18,520
営業費用 60,963 59,680 56,398 67,186 58,138 52,427 53,793 59,667 60,052 52,968 52,569 63,526 61,916 68,630 61,272 83,691 73,295 72,180 75,288 78,358 79,004 68,626 77,628 100,071 92,338 87,184 94,872 95,220 98,149 77,024 66,809 71,113 51,698 37,929 26,653 32,081 35,329 29,872 24,453 23,805 25,710 29,961 27,705 27,954 29,822 28,920 26,445 25,879
営業利益 - -56,706 -50,062 -65,753 -37,737 -45,293 -43,095 -55,774 -41,642 -47,497 -33,494 -57,834 -58,829 -65,121 -56,997 -79,176 -64,976 -48,704 -62,450 -62,621 -73,666 -42,476 -65,201 -70,572 -72,476 -72,176 -76,615 -76,490 -83,892 -64,110 -53,615 -56,167 -38,502 -26,879 -14,202 -17,432 -24,912 -16,123 -8,760 -6,240 -11,207 -15,705 -10,837 -9,200 -14,434 -2,725 -6,455 20,012
営業利益率 (%) - -49.1 -93.8 -10.4 -32.3 43.6
経常(税引前)利益 - -56,492 -49,394 -64,770 -37,526 -45,089 -42,991 -55,661 -41,456 -47,189 -33,150 -58,765 -59,936 -65,833 -66,009 -79,933 -64,943 -47,608 -60,092 -53,442 -72,500 -39,637 -63,983 -65,557 -82,906 -62,848 -73,550 -67,233 -79,452 -52,625 -35,315 -32,185 -25,422 -8,196 -16,023 -14,259 -22,483 -14,187 -7,583 -5,016 -10,402 -15,221 -10,052 -8,939 -14,138 73,206 -2,889 73,068
経常(税引前)利益率(%) - -1899.5 -779.6 -4519.9 -183.9 -632.0 -401.9 -1429.8 -225.2 -862.5 -173.8 -1032.4 -1941.6 -1876.1 -1544.1 -1770.4 -780.7 -202.8 -468.1 -339.6 -1358.2 -151.6 -514.9 -222.2 -417.4 -418.8 -402.9 -359.0 -557.3 -407.5 -267.7 -215.3 -192.6 -74.2 -128.7 -97.3 -215.8 -103.2 -48.3 -28.6 -71.7 -106.8 -59.6 -47.7 -91.9 279.5 -14.5 159.2
法人税等合計 - 1,723 5,101 -460 4,948 2,514 4,323 -10,835 694 36 812 8,568 5,383 454 868 6,989 144 -6,790 -659 -3,256 80 201 -5,552 71 100 39 100 -8,800 200 -220 -7 -173 500 -5 -488 -3 -395 1,500 1,400 3,500 1,300 1,308 2,646 6,600 -600 18,371 -6,500 12,052
実効税率(%) - -73.8 4.2 25.1 225.0 16.5
純利益 -60,018 -58,215 -54,495 -64,310 -42,474 -47,603 -47,314 -44,828 -42,150 -47,225 -33,962 -67,332 -65,319 -66,287 -66,877 -86,922 -65,087 -40,818 -59,433 -50,186 -72,580 -39,838 -58,431 -65,606 -83,053 -62,887 -73,643 -58,434 -79,679 -52,405 -35,308 -32,034 -25,946 -8,191 916,631 -10,362 -22,088 -15,645 -8,950 -8,510 -11,664 -16,529 -12,698 -15,527 -13,579 54,835 3,615 61,024
純利益率(%) -82.8 -88.2 209.3 18.1 133.0
一株あたり利益 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -0.48 -0.43 -0.34 -0.11 12.14 -0.15 -0.35 -0.28 -0.17 -0.17 -0.24 -0.34 -0.26 -0.31 -0.27 1.09 0.07 1.2
希薄化後一株あたり利益 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -0.48 -0.43 -0.65 -0.11 12.14 -0.15 -0.35 -0.28 -0.17 -0.17 -0.24 -0.34 -0.26 -0.31 -0.27 1.08 0.07 1.15
EBITDA - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EBITDAマージン(%) - - - - - - - - - - - - - - - - - - - - - - - - - - - -